UK's Oxford Biomedica rises after multi-year commercial supply deal with BMS

Bristol-Myers Squibb Co

04/02/2026 08:45

** Shares of British cell and gene therapy manufacturer Oxford Biomedica OXB.L up 1.8% at 835 pence

** Co says it expanded its partnership with Bristol Myers SquibbBNY.N, signing a new commercial supply agreement to make and supply lentiviral vectors for BMS' CAR‑T programmes

** Under agreement, OXB expects to start commercial manufacturing in 2026, pending regulatory approval of the CAR‑T products.

** In 2025, OXB gained 47%

 (Reporting by Megha Kumari in Bengaluru)

 ((Megha.Kumari@thomsonreuters.com))